| Document Type
|
:
|
BL
|
| Record Number
|
:
|
965405
|
| Doc. No
|
:
|
b719775
|
| Title & Author
|
:
|
Peptide-based cancer vaccines /\ [edited by] W. Martin Kast.
|
| Publication Statement
|
:
|
Georgetown, Tex. :: Landes Bioscience ;Austin, Tex. :: Eurekah.com,, ©2000.
|
| Series Statement
|
:
|
Medical intelligence unit ;; 24
|
| Page. NO
|
:
|
1 online resource (239 pages) :: illustrations
|
| ISBN
|
:
|
0585408734
|
|
|
:
|
: 1587064081
|
|
|
:
|
: 1597342386
|
|
|
:
|
: 9780585408736
|
|
|
:
|
: 9781587064081
|
|
|
:
|
: 9781597342384
|
|
|
:
|
1587060264
|
|
|
:
|
9781587060267
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index.
|
| Contents
|
:
|
Front Cover -- Inside Front Cover -- Table of Contents -- Preface -- Chapter 1: Identification and Selection of T-Cell Epitopes Derived from Tumor-Associated Antigens for the Development of Immunotherapy for Cancer -- Chapter 2: Mutant Oncogene and Tumor Suppressor Gene Products and Fusion Proteins Created by Chromosomal Translocations as Targets for Cancer Vaccines -- Chapter 3: p53-A Target for T-Cell Mediated Immunotherapy -- Chapter 4: Critical Dependence of the Peptide Delivery Method on the Efficacy of Epitope Focused Immunotherapy.
|
|
|
:
|
Chapter 13: Gp100 and G250-Towards Specific Immunotherapy Employing Dendritic Cells in Melanoma and Renal Cell Carcinoma -- Chapter 14: Melanoma Peptide Clinical Trials -- Index: A-E -- Index: E-M -- Index: M-W.
|
|
|
:
|
Chapter 5: Cancer Peptide Vaccines in Clinical Trials -- Chapter 6: Carcinoembryonic Antigen (CEA) Peptides and Vaccines for Carcinoma -- Chapter 7: Studies of MUC1 Peptides -- Chapter 8: Cytotoxic T Cell Epitopes and Tissue Distribution of the HER-2/neu Proto-Oncogene-Implications for Vaccine Development -- Chapter 9: Clinical Trials of HER-2/neu Peptide-Based Vaccines -- Chapter 10: Peptides in Prostate Cancer -- Chapter 11: Peptides in Cervical Cancer -- Chapter 12: Peptide Vaccines for the Treatment of Melanoma.
|
| Abstract
|
:
|
The field of peptide based cancer vaccines has evolved tremendously in the last decade of this century. The exploration on how to apply the peptide knowledge for vaccination purposes began when it was demonstrated that these peptides after being mixed into adjuvants actually induced T cell responses that could prevent virus infections and tumor growth in experimental animal models.
|
| Subject
|
:
|
Cancer-- Immunotherapy.
|
| Subject
|
:
|
Peptide drugs.
|
| Subject
|
:
|
Vaccines.
|
| Subject
|
:
|
Cancer-- Immunotherapy.
|
| Subject
|
:
|
HEALTH FITNESS-- Diseases-- Cancer.
|
| Subject
|
:
|
MEDICAL-- Oncology.
|
| Subject
|
:
|
Peptide drugs.
|
| Subject
|
:
|
Vaccines.
|
| Subject
|
:
|
Cancer Vaccines.
|
| Subject
|
:
|
Neoplasms-- drug therapy.
|
| Subject
|
:
|
Immunotherapy-- methods.
|
| Subject
|
:
|
Peptides-- therapeutic use.
|
| Dewey Classification
|
:
|
616.99/406
|
| LC Classification
|
:
|
RC271.I45P46 2000eb
|
| NLM classification
|
:
|
QZ 267P4235 2000
|
| Added Entry
|
:
|
Kast, W. Martin.
|